相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Modeling buprenorphine reduction of fentanyl-induced respiratory depression
Erik Olofsen et al.
JCI INSIGHT (2022)
Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses in the US, 2010-2017
Ashley H. Hirai et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Prenatal Opioid Analgesics and the Risk of Adverse Birth Outcomes
Susan B. Brogly et al.
EPIDEMIOLOGY (2021)
Outcomes associated with the use of medications for opioid use disorder during pregnancy
Elizabeth E. Krans et al.
ADDICTION (2021)
Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation
Olena Anoshchenko et al.
DRUG METABOLISM AND DISPOSITION (2021)
Neonatal Abstinence Syndrome Incidence and Health Care Costs in the United States, 2016
Andrea E. Strahan et al.
JAMA PEDIATRICS (2020)
In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome
Bryce A. Griffin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids
Keith M. Olson et al.
PLOS ONE (2019)
Prenatal Risk Factors and Perinatal and Postnatal Outcomes Associated With Maternal Opioid Exposure in an Urban, Low-Income, Multiethnic US Population
Romuladus E. Azuine et al.
JAMA NETWORK OPEN (2019)
Opioid Use Disorder Documented at Delivery Hospitalization - United States, 1999-2014
Sarah C. Haight et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development
Scott L. Harbeson et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs
Zufei Zhang et al.
DRUG METABOLISM AND DISPOSITION (2017)
Maternal Buprenorphine Dose at Delivery and Its Relationship to Neonatal Outcomes
Alane B. O'Connor et al.
EUROPEAN ADDICTION RESEARCH (2016)
Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors
Jai Shankar K. Yadlapalli et al.
PHARMACOLOGICAL RESEARCH (2016)
Predictors of neonatal abstinence syndrome in buprenorphine exposed newborn: can cord blood buprenorphine metabolite levels help?
Darshan Shah et al.
SPRINGERPLUS (2016)
Birth and Neonatal Outcomes Following Opioid Use in Pregnancy: A Danish Population-Based Study
Mette Norgaard et al.
SUBSTANCE ABUSE-RESEARCH AND TREATMENT (2015)
Altering Metabolic Profiles of Drugs by Precision Deuteration: Reducing Mechanism-Based Inhibition of CYP2D6 by Paroxetine
Vinita Uttamsingh et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Opioid Abuse and Dependence during Pregnancy Temporal Trends and Obstetrical Outcomes
Ayumi Maeda et al.
ANESTHESIOLOGY (2014)
Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy
Hendree E. Jones et al.
DRUG AND ALCOHOL DEPENDENCE (2014)
Buprenorphine exposure in infants of opioid-dependent mothers at birth
Anne E. Bartu et al.
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY (2012)
Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice
Hisham Alhaddad et al.
CRITICAL CARE MEDICINE (2012)
P-Glycoprotein Is a Major Determinant of Norbuprenorphine Brain Exposure and Antinociception
Sarah M. Brown et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Hendree E. Jones et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Maternal Buprenorphine Dose, Placenta Buprenorphine, and Metabolite Concentrations and Neonatal Outcomes
Marta Concheiro et al.
THERAPEUTIC DRUG MONITORING (2010)
Correlations of Maternal Buprenorphine Dose, Buprenorphine, and Metabolite Concentrations in Meconium With Neonatal Outcomes
S. L. Kacinko et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Buprenorphine activates μ and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by μ receptor activation in the rat formalin test
Tatsuo Yamamoto et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Novel metabolites of buprenorphine detected in human liver microsomes and human urine
Y Chang et al.
DRUG METABOLISM AND DISPOSITION (2006)
Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain
T Christoph et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Aromatase is the major enzyme metabolizing buprenorphine in human placenta
SV Deshmukh et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
分享论文
